Background-Transcatheter (percutaneous) pulmonary valve (TPV) replacement has emerged as a viable therapy for right ventricular outflow tract conduit dysfunction. Little is known about the incidence, clinical course, and outcome of infective endocarditis (IE) after TPV implant. We reviewed combined data from 3 ongoing prospective multicenter trials to evaluate the experience with IE among patients undergoing TPV replacement using the Melody valve. Methods and Results-Any clinical episode reported by investigators as IE with documented positive blood cultures and fever, regardless of TPV involvement, was considered IE. Cases were classified as TPV-related if there was evidence of vegetations on or new dysfunction of the TPV. The 3 trials included 311 patients followed for 687.1 patient-years (median, 2.5 years). Sixteen patients were diagnosed with IE 50 days to 4.7 years after TPV implant (median, 1.3 years), including 6 who met criteria for TPV-related IE: 3 with vegetations, 2 with TPV dysfunction, and 1 with both. The annualized rate of a first episode of IE was 2.4% per patient-year and of TPV-related IE was 0.88% per patient-year. Freedom from TPV-related IE was 97±1% 4 years after implant. All patients were treated with intravenous antibiotics, 4 had the valve explanted, and 2 received a second TPV. There was 1 sepsis-related death, 1 patient died of sudden hemoptysis, and 2 patients developed recurrent IE. Conclusions-Bacterial endocarditis has occurred in all 3 prospective multicenter studies of the Melody valve in North America and Europe. Most cases did not involve the TPV and responded to antibiotics. More data are necessary to understand risk factors in this population. Clinical Trial Registration-URL: http://www.clinicaltrials.gov. Unique identifiers: NCT00740870, NCT01186692, and NCT00688571. (Circ Cardiovasc Interv. 2013;6:292-300.) Key Words: endocarditis ◼ pulmonary regurgitation ◼ pulmonary stenosis ◼ pulmonary valve ◼ Ross procedure ◼ tetralogy of Fallot
T ranscatheter pulmonary valve (TPV) replacement with a stent-mounted bovine jugular venous valve was first reported in 2000. 1 Subsequently, single and multicenter studies of patients with right ventricular outflow tract (RVOT) conduits or bioprosthetic valves have confirmed that TPV replacement using the Melody valve (Medtronic Inc, Minneapolis, MN) reduces RVOT obstruction and provides a competent pulmonary valve. [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] Among these studies and in other focused reports, several cases of infective endocarditis (IE) after TPV implant have been described. 2, [11] [12] [13] [14] [15] [16] IE is a potentially lethal complication of surgically implanted valve prostheses and other intracardiac devices. [17] [18] [19] Insofar as transcatheter valves used on both the left 20 and right sides of the heart are intracardiac prostheses, IE should be anticipated. With increasing use of the Melody TPV, it is important to assess and report the experience with this outcome in all 3 manufacturer-sponsored prospective multicenter studies of the Melody valve that are currently ongoing in North America and Europe.
Methods

Study Subjects and Protocols
This study included all patients in whom a Melody TPV (Medtronic Inc) was implanted in the RVOT as part of the 3 ongoing prospective multicenter studies sponsored by Medtronic: (1) the Post-Approval Study of the original US Investigational Device Exemption (IDE) cohort, (2) the US Post-Approval Study (PAS), and (3) the Melody TPV Post-Market Surveillance Study (PMSS) in Europe and Canada. In the IDE Study, 150 patients received a Melody valve at 5 US centers between January 2007 and January 2010; these patients are now being followed under a postapproval protocol (ClinicalTrials.gov identifier: NCT00740870). The details of this study protocol and procedural and short-term outcomes were published previously. 3, 4, 21 The database for this study was locked for the present analysis on June 18, 2012, although 1 TPV explant that was scheduled before the database lock and occurred within a week of that date was included. The US PAS was commissioned to collect data on 100 additional Melody TPV implants at 10 new centers after the device was approved by the Food and Drug Administration (ClinicalTrials.gov identifier: NCT01186692). Of the planned 100 implants, 98 had been performed (between July 2010 and May 2012) when the database was locked for this analysis on June 18, 2012. The PMSS prospectively enrolled a total of 63 subjects who underwent Melody valve implant at 7 centers in Europe and Canada between October 2007 and April 2009 (ClinicalTrials. gov identifier: NCT00688571); the database was locked for this analysis on July 25, 2012 . Protocols similar to that used in the IDE study were followed for the PAS and PMSS. Investigative sites for the 3 studies are listed in Appendix A in the online-only Data Supplement. Patients in all 3 studies provided written informed consent. Data on patients, procedures, and outcomes were obtained from the prospective, deidentified databases maintained by the study sponsor. Some of the data specific to the reported episodes of IE (eg, treatment) were collected on predetermined study case report forms, whereas other information (eg, organism, presence of vegetations) was collected retrospectively, as part of a quality control process. Although active IE was a specified exclusion criterion for the trials, 3 the study sponsor did not routinely collect information about potentially predisposing circumstances (including prior history of IE) or laboratory data other than blood culture results. Such data were generally reported when available, but cases of IE were not always diagnosed or treated at the implanting institution, and the evaluation and management were not necessarily under the direct guidance of the investigators.
By protocol, patients received periprocedural intravenous antibiotics at the time of implant, according to institutional practice, typically cefazolin or a similar agent unless the patient was allergic to penicillin or cephalosporins. Neither postimplant IE prophylaxis nor aspirin therapy was specifically required in the study protocols, but both are recommended in the Melody valve instructions for use, which were included as an appendix to the protocols. Information about whether patients in these clinical trials were taking antiplatelet medications or antibiotic prophylaxis was not routinely collected.
Ascertainment of Cases and Definition of IE
Cases of IE were ascertained from the prospective study databases maintained by Medtronic. The diagnosis of IE was determined by the implanting investigator and entered in the study database as an adverse event. The case report forms used in the studies included 2 different types of IE events: endocarditis, TPV-related and endocarditis, not TPV-related, which were not further defined and were assigned by the investigator. The database was also queried for any other reported infectious events not coded as IE by the investigator, which met the definitions of IE used in this analysis. The diagnosis of IE was not independently adjudicated as part of the studies. No diagnostic or therapeutic sequences were prescribed by the study protocols for patients diagnosed with IE, and no specific recommendations were made regarding intervention.
The study protocols made reference to the modified Duke criteria for assessment of IE, but cases of IE in this study were not characterized according to those or other published criteria, primarily because sufficient data were not always available to determine the status for all the Duke criteria. 22, 23 For this analysis, we included all reported cases of definite or presumed IE, which was defined as any clinical episode entered into the study database by the implanting investigator as IE or infection, as long as the patient presented with a febrile illness and had confirmatory blood cultures with an organism known to cause IE. Thus, the definition of IE for this study ensured that all patients had at least possible IE by the modified Duke criteria because all had a minimum of 1 major and 2 minor criteria or 3 minor criteria (ie, fever, a predisposing condition, and ≥1 but usually multiple positive blood cultures with IE-causing organisms). 22 However, because limited availability of data in some cases precluded distinction between definite and possible IE, cases were not characterized according to these criteria. 22 Cases of IE were subdivided into TPV-related and not TPV-related based on evidence of TPV leaflet or conduit involvement, regardless of the adverse event code originally assigned by the investigator. TPV-related IE was defined as any case in which there was (1) echocardiographic or pathological evidence of vegetations on the TPV or conduit, and (2) evidence of new or progressive TPV dysfunction (stenosis or regurgitation) associated with the episode of IE (ie, since the prior protocol evaluation). If the TPV leaflets were not visualized during the evaluation of the IE episode and there was no evidence of new or progressive TPV dysfunction, the case was characterized as not TPV-related.
Valves explanted at surgery or autopsy and returned to Medtronic were systematically evaluated by a cardiac pathology core laboratory. Findings from those reports are presented for the valves explanted in this series. A liberal definition of TPV involvement was maintained such that the clinical diagnosis of TPV-related IE was only supplanted by the pathological findings if the latter showed TPV involvement. Thus, if a valve categorized as having TPV-related IE based on echocardiographic evidence of valve dysfunction was subsequently found on pathological examination to have no evidence of IE involving the TPV, the original classification of TPV-related IE was not changed. However, if an episode was characterized clinically as not TPVrelated but the device was found on pathological examination to have evidence of IE affecting the valve, it was reclassified as TPV-related.
Data Analysis
Data analysis for this study was primarily descriptive. As a result of the relatively small number of events, variable information collected in the 3 studies, and lack of some diagnostic/anatomic information that we considered to be of particular hypothetical interest, extensive testing of associations was not performed. Annualized event rates were calculated using the total patient follow-up until death, TPV explant, or most recent evaluation under the study protocol, including both initial and any recurrent episodes of IE as events. An annualized rate of a first episode of IE was calculated in a similar manner, including only initial IE episodes as events and truncating follow-up duration at the time of the initial diagnosis of IE. Freedom from a diagnosis of IE and freedom from TPV-related IE after TPV implant were assessed using the Kaplan-Meier method. Analysis of a limited
WHAT IS KNOWN
• Little is known about the incidence, clinical course, and outcome of endocarditis after transcatheter pulmonary valve implant.
• The existing literature is limited to case reports and small case series.
WHAT THE STUDY ADDS
• Data on infective endocarditis after transcatheter pulmonary valve replacement from 3 ongoing prospective multicenter trials in North America and Europe.
• Provides a preliminary estimate of the frequency and outcomes of endocarditis after transcatheter pulmonary valve replacement in the short-term.
• Insight into the clinical and bacteriologic spectrum of endocarditis in this population. number of consistently available preimplant and early postimplant variables was performed using log-rank testing or Cox proportional hazards regression. For estimation of time-related outcomes, patients without IE were censored event-free at the date of most recent protocol follow-up, death, or TPV explant. Data are presented as frequency or median (minimum-maximum). Hazard ratios and incidence rates are presented with 95% confidence intervals.
Results
Frequency and Characteristics of IE
Overall, the 3 studies included 311 patients with a total of 687.1 patient-years of follow-up (median, 2.5 years; maximum, 5.1 years). Of these 311 patients, 16 were diagnosed with definite or presumed IE; 10 of these patients were in the IDE trial (442.7 patient-years of follow-up) and 3 each were in the PAS (59.2 patient-years) and PMSS (185.2 patientyears). Demographic and diagnostic data for the 16 patients are summarized in Table 1 , and details related to the cases of IE are provided in Table 2 . One of these cases of IE was reported in a prior publication. 11 The total duration of followup through the initial diagnosis of IE or most recent protocol evaluation was 679.4 patient-years, giving an annualized rate of first IE episode of 2.4% (95% confidence interval, 1.4%-3.8%) per patient-year. All but 3 of these patients were diagnosed ≥6 months after the TPV implant, and the median duration from implant to diagnosis was 1.3 years (50 days-4.7 years). Freedom from a diagnosis of IE after TPV implant by Kaplan-Meier analysis was 96±1% at 2 years and 92±4% at 4 years. On limited testing of the demographic and preimplant diagnostic factors listed in Table 1 , there were no statistically significant associations with shorter time to IE. There were no differences in freedom from IE between patients in the 3 trials or according to implant order within a given trial.
Of the 16 patients with definite or presumed IE, 6 met our definition of TPV-related IE: 3 with vegetations on the TPV, 2 with new/progressive hemodynamic dysfunction of the TPV, and 1 with both. All 3 cases with TPV dysfunction had stenosis: 1 had vegetations, 1 did not, and in 1 the leaflets could not be visualized. Of the 6 cases of TPV-related IE, 2 were from each trial. The annualized rate of a first episode of TPV-related IE was 0.88% (95% confidence interval, 0.32%-1.9%) per patient-year, and freedom from TPV-related IE was 98±1% at 2 years and 97±1% at 4 years. By univariable Cox regression of the variables listed in Table 1 , higher preimplant RVOT gradient (hazard ratio, 1.6 per 10 mm Hg [1.1-2.4]; P=0.04) and higher early postimplant RVOT gradient (hazard ratio, 2.2 per 10 mm Hg [1.2-4.3]; P=0.03) were associated with shorter time to TPV-related IE. Other than the potentially extenuating circumstances associated with IE diagnosis that are reported in Table 2 , no patients were known to have undergone procedures placing them at risk for bacteremia, leading to the episode of IE. †Of the 6 patients with TPV-related IE, 2 had mean gradients less than the median of the overall cohort (9 mm Hg and 16 mm Hg).
Treatment and Outcomes of IE
A flow diagram of cases and outcomes is presented in Figure 1 . All patients were treated with intravenous antibiotics. The TPV was explanted surgically after the first episode of IE in 3 patients with TPV-related IE, 1 acutely in the context of septic syndrome (no vegetations but new TPV obstruction) and 2 after medical therapy (both with vegetations on the Melody valve, 1 also with vegetations on a ventricular pacing wire, and 1 with progressive vegetation-associated TPV obstruction). Two other patients with TPV obstruction underwent transcatheter implant of a second Melody valve within the first after antibiotic therapy and sterilization of blood cultures. In one of these patients, the TPV obstruction was newly recognized after the onset of IE (classified as TPV-related IE based on increasing RVOT obstruction), whereas in the other (not classified as TPV-related IE), there was stenosis related to a known type II stent fracture for which catheterization had already been planned when the patient developed IE. Two patients with TPV-related IE ultimately died. One of these patients initially presented with sepsis and died after a long hospital course that included TPV explant and surgical pulmonary valve replacement, as well as multiple complications. The other patient had vegetations on the aortic valve without valve dysfunction at the initial presentation and was found to have an increased RVOT gradient but no evidence of TPV-associated vegetations or stent fracture. After antibiotic therapy resulted in sterilization of blood cultures and resolution of the aortic valve vegetations, a second TPV was placed for progressive RVOT obstruction. Three weeks later, the patient presented with shock as a result of pulmonary hemorrhage, apparently from a ruptured aortopulmonary collateral, but with no evidence of active infection, IE, or valve dysfunction, and died soon thereafter of multisystem failure. On autopsy, the second Melody valve reportedly had no evidence of IE, but the device was not examined by the pathology core laboratory, and no further details of the pathological evaluation were available.
Two patients presented with recurrent IE 1.6 and 2.7 years after the initial diagnosis, both with the same organism as in the first episode, bringing the total number of IE events to 18. Thus, including recurrent IE, the annualized rate of IE during the total 687.1 patient-years of followup was 2.6% (95% confidence interval, 1.6%-4.1%) per patient-year. One of these patients had a second TPV placed for stent fracture-related RVOT obstruction after medical treatment of the initial IE episode, and the other was 1 of 2 patients with TPV-associated vegetations at the initial diagnosis who did not undergo TPV explant. Neither of these patients had clear TPV involvement with the second IE episode, but 1, who was 5.5 years out from the original TPV implant, elected to undergo Melody valve explant and surgical pulmonary valve replacement after medical treatment of recurrence. Thus, a total of 4 patients (3 with TPV-related IE) had the Melody valve explanted after an initial or recurrent episode of IE.
Three of the 4 surgically explanted valves were available for pathological evaluation by the core laboratory, all of which met our definition of TPV-related IE. For the first explanted TPV, which had vegetations associated with the valve on echocardiography but no stenosis or regurgitation, gross inspection revealed diffuse involvement of the luminal aspect of all 3 leaflets by large vegetations, including in the sinuses between the leaflets and vein wall, as well as tan friable material consistent with infected debris on the adventitial aspect of the device (Figure 2 ). Microscopic evaluation was consistent with acute bacterial IE involving both the luminal and adventitial aspects of the TPV. A second explanted TPV, which had large vegetations visible on echocardiography that seemed to be the cause of progressive RVOT obstruction, had similar pathological findings, with friable vegetations involving all 3 leaflets. A third explanted TPV, which was obstructed and without evidence of vegetations on echocardiography (valve not visualized), had stent fractures, but no sign of IE on pathological examination.
At most recent follow-up, 5 of the 16 patients with IE, 4 of whom had TPV-related IE, had died (n=2) or undergone Melody valve explant (n=4, 1 subsequently died). Among the 11 remaining patients, 1 with a history of TPV-related IE, the median duration of follow-up after the IE diagnosis was 234 days (0-454 days); the median mean Doppler RVOT gradient was 15 mm Hg (8-34 mm Hg), and no patient had more than trivial regurgitation of the Melody valve.
Discussion
IE in Patients With a Melody Valve
As this study and prior reports 2,11-16 document, IE can and does occur after TPV replacement using the Melody valve. Given the small number of cases, robust risk factors for this outcome are yet to be determined. Nevertheless, some important observations can be made and preliminary conclusions drawn from the data available in this combined experience from 3 ongoing prospective, multicenter studies in North America and Europe. One notable finding was that the episodes of IE in this series were not acute, with the earliest case diagnosed 50 days after implant and all but 3 diagnosed ≥6 months after implant. Subacute presentation of IE was also generally the case in prior series. 2, 15 Also, blood cultures grew a variety of bacteria known to cause IE. Thus, in this limited analysis, the observed cases of IE did not seem to be procedural complications and were unlikely to be due to systematically contaminated product.
Another important finding of this study was that most reported cases of IE did not clearly involve the TPV per se. Furthermore, of the 3 cases defined clinically as TPV-related IE for which the explanted device was evaluated by the pathology core laboratory, only 2 showed pathological evidence of IE involving the TPV. The other valve, which was categorized as TPV-related IE on the basis of progressive obstruction, was likely misclassified, as it was found to have a type II stent fracture, which is associated with recurrent RVOT obstruction, 21 but no pathological evidence of IE. Thus, using an intentionally inclusive definition, we may have overestimated the true rate of TPV-related IE. It is also noteworthy that most of the reported cases of IE in this study responded to intravenous antibiotic therapy, with no known progression from non-TPV-related to TPV-related IE. From these findings, it is reasonable to propose that TPV explant is not required during the acute treatment of IE when there is no evidence of TPV involvement. We do not have sufficient data to determine whether antibiotic therapy without explant is appropriate in the setting of TPV-related IE. Similarly, given the small number of patients undergoing transcatheter intervention for TPV dysfunction after IE, our data do not permit conclusions about the safety of repeat balloon expansion or Melody valve-in-Melody valve therapy in these circumstances.
Risk Factors and Contributing Conditions
It is unclear whether the risk of IE in patients with a Melody TPV differs from that in patients with other implanted devices in the RVOT. The most common surgical prostheses used to reconstruct the RVOT in patients with congenital heart disease or after a Ross procedure are valved homografts, Contegra conduits (which are made from the same valved bovine jugular venous tissue used in the Melody valve), and various other bioprosthetic valves and valved conduits. Data on IE in patients with these types of pulmonary conduits or valves are limited and can be drawn primarily from case reports or as isolated cases within surgical follow-up series ( Table 3) . [24] [25] [26] [27] [28] [29] [30] [31] [32] [33] One of the shortcomings of the literature in this regard is that IE may not always be considered an index outcome in surgical series and often seems to be reported only or primarily when it leads to RVOT reoperation. For example, in addition to the studies included in the selected literature review in Table 3 , which only includes series in which ≥1 case of IE was reported, there are many surgical studies that do not mention any cases of IE. Thus, there is no appropriate benchmark against which to assess IE rates after TPV implant. Similarly, there is little published outcome data on other valves used for TPV replacement, 34 precluding meaningful comparison with the Melody valve.
Despite the limited data on IE after RVOT conduit or valve surgery, this complication has been reported with most of the surgical RVOT prostheses that are used. [24] [25] [26] [27] [28] [29] [30] [31] [32] [33] Judging by the available literature, including studies other than those in Table 3 that report no cases of IE, 35, 36 the rate of IE in Contegra conduits is not substantially different than in other types of surgical pulmonary valve or conduit. In a recent case series of IE after Melody valve implant, Patel et al 15 speculated that, "inherent biological characteristics of the Contegra valve and its method of preparation maybe contributing to the thrombogenicity and possible tropism for microorganisms." The available data do not seem sufficient to support this theory, but the possibility that there is an element of IE risk specifically related to the tissue composition of the Melody valve deserves consideration.
Regardless of the risk of IE in patients with a Melody valve compared with other RVOT prostheses, it is worth considering whether specific features of the TPV device or its implanted configuration or environment can introduce a unique risk for infection. In a recent report, Patel et al 15 described 4 patients who presented with fever, severe RVOT obstruction, and positive blood cultures 2.6 to 28.3 months after Melody valve implant into relatively small-diameter conduits. All 4 were found on explant or autopsy to have thrombus and vegetations in the outflow aspect of the TPV. The authors reported that 3 of the 4 episodes were preceded by discontinuation of aspirin therapy. Based on the similar clinical presentations and the finding of thrombus in all of their patients, they proposed an etiologic pathway for Melody valve IE, beginning with a residual gradient and turbulence (from incomplete opening of the valve when implanted in a relatively small conduit), which predisposes to thrombosis; discontinuation of antiplatelet therapy then incites the formation of thrombus, which exacerbates the turbulence and becomes a nidus for seeding by microorganisms. Data from the current multicenter study are not sufficient to support or dispel this theory, but it may include salient elements, such as the role of RVOT obstruction in at least some cases of IE. However, although a higher postimplant gradient was associated with a shorter freedom from TPV-related IE, it was not a necessary condition in this series, insofar as 2 of the 6 patients with TPV-related IE had mean gradients below the median of the overall cohort. Also, thrombus was not a prominent feature of the explanted valves examined by our pathology core laboratory.
Other than its tissue composition, there are features of the implanted Melody valve that may differ from surgically implanted pulmonary valves and that may contribute to environmental circumstances that potentially pose a unique risk for infection. For example, the Melody valve is expanded within an existing conduit or valve and maintained in position by friction between the device and conduit along the apposed surfaces. Given the variable shape, contour, and compliance of the conduits into which the Melody valve is deployed, the implanted geometry of the Melody valve can be quite irregular, and there is often incomplete apposition, which introduces the potential for pockets of space of variable size and shape between the adventitial surface of the TPV and the conduit wall. Also, the leaflets of the jugular venous valve tend to have a long coaptation surface, and depending on the extent to which the Melody device is expanded, there may be considerable redundancy of the leaflets. Neither these nor other potentially important features of the implanted TPV were evaluated for this analysis, and we cannot address their potential relationship to IE. Nevertheless, it is important to recognize that there may be unique features of the Melody valve in situ that potentially modify the risk of intravascular complications, such as thrombosis and IE, and to consider such features during future investigations.
In the 3 studies included in this analysis, data were not routinely collected to ascertain compliance with antibiotic prophylaxis, use of antiplatelet therapy, dentition, or other potentially relevant factors. Nevertheless, extenuating circumstances, including prior history of IE, open oral or cutaneous lesions, and other predisposing conditions, were present in nearly two thirds of the 18 episodes of IE. Particularly noteworthy is the fact that 2 of the 16 patients with IE in this series had documented episodes of IE before TPV implant. Lurz et al 2 reported IE in 5 of 155 patients at a median of ≈5 months after TPV replacement, all of whom had potentially predisposing factors, including prior episodes of IE in 2. It is reasonable to assume that predisposing factors for IE in other circumstances will increase the risk of IE after TPV replacement as well. Of particular concern is the extent to which prior IE increases the likelihood of IE after TPV replacement; the additive risk of such a history is unclear, but our cases and those of Lurz et al 2 suggest that it may be important.
Anticipation and Prevention
This primarily descriptive experience permits minimal insight into the pathogenesis or pathophysiology of IE in patients with a Melody valve, but it does highlight the need for awareness and education. The Melody valve is a prosthetic valve. Thus, prophylaxis against IE should be followed as recommended by the American Heart Association and the American College of Cardiology. 23, 37 This recommendation should be recognized by implanters of the Melody valve and clearly indicated in the medical record and in communication with patients, families, and referring physicians. Similarly, the importance of dental hygiene should be reinforced. 38 Of course, these practices alone will not eliminate the risk, and there are no data to support their benefit in this context. Furthermore, our data do not suggest that they were particularly relevant in this cohort, but they are central concepts in preventive efforts, in general, and should be emphasized.
This cohort included all patients identified and reported by the implanting physician as presenting with possible IE who met the relatively liberal criteria of positive blood cultures in the setting of a febrile illness. A low threshold for diagnosing and treating IE in this population seems appropriate, and we think that satisfaction of the modified Duke criteria should not be necessary to institute therapy in the setting of a Melody TPV valve. The potential risks of disease progression are probably sufficient to justify antibiotic treatment based on simpler diagnostic information, even if such an approach results in circumstantial treatment of patients without true IE. In addition, it can be difficult to visualize the RVOT and the leaflets of the TPV on echocardiography, which may limit the ability to identify vegetations and confound the distinction between TPV-related and TPV-unrelated IE. Thus, aggressive medical management presuming TPV involvement, regardless of whether vegetations are seen, seems to be a prudent approach that may help reduce the chance of progression.
Our finding that higher pre-and postimplant RVOT gradients were associated with shorter freedom from TPV-related IE should be interpreted with caution, given the small number of cases. Also, even if true, this association does not establish a causal relationship between TPV obstruction and IE. Of course, it stands to reason that IE is more likely to develop in patients with important TPV obstruction, given that turbulent flow is a risk factor for IE in general. Although these observations and speculations are not sufficient to support an argument that maximal reduction of RVOT gradient at the time of Melody valve implant will decrease the risk of IE, they do offer a convenient reminder that a limitation of TPV therapy can be residual or recurrent obstruction and that implanters should strive to maximize gradient reduction at the time of TPV implant. 9, 11, 12, 21 
Limitations
This experience is primarily descriptive and is limited by relatively small numbers, self-reporting of data about IE by investigators at multiple centers, and insufficient data to assess risk factors. It is possible that there was ascertainment bias, with cases under-reported as a result of self-resolving infection or unexplained death. We attempted to offset any such bias by including all patients reported as having IE, regardless of valvar involvement or satisfaction of rigorous diagnostic criteria, and by using an inclusive definition of TPV-related IE. As mentioned above, it may be difficult to visualize the RVOT and the Melody valve with echocardiography, and cases of TPVrelated IE with small vegetations and no significant valve dysfunction may have been misclassified as not TPV-related. On the other hand, given our inclusive definition of IE, it is possible that some of the patients without clear TPV involvement simply had bacteremia rather than IE. Also, we likely misclassified ≥1 case as TPV-related IE on the basis of progressive RVOT obstruction that was related to stent fractures rather than IE. Our ability to contextualize the findings of this report is also limited by the lack of adequate comparative data on IE after surgical placement of other RVOT conduits and valves.
Conclusions
From this analysis, it is clear that IE may occur after TPV replacement using the Melody valve. Although the rate of IE depends on the threshold for definition and a true understanding of its extent will require longer follow-up in larger series of patients, the data from the 3 multicenter prospective trials included in this analysis may offer the best available opportunity to assess the frequency and clinical features of IE after Melody valve implant. Case reports and small case series, while potentially valuable, offer a focused view and do not necessarily provide an appropriate context in which to evaluate the reported findings. Our interpretation of the data presented in this study and the conclusions and recommendations drawn from them are necessarily limited but will hopefully provide a foundation for ongoing investigation of this important issue.
